Novo-Nordisk A/S plummeted 27% this month, marking the worst month since the Internet bubble, suffering a huge loss in Market Cap in the European stock market.

Novo-Nordisk A/S's stock price has plummeted over 27% this month, setting the worst single-month record since 2002. Since June last year, Novo-Nordisk A/S has faced a series of bearish developments, including the demand for weight-loss drugs Wegovy and Ozempic falling short of expectations, disappointing mid-term trial results for the oral weight-loss drug monlunabant, and poor data performance from another investigational injectable drug, CagriSema. However, Wall Street remains generally optimistic about the stock.

wallstreetcn16:29 ET

Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%

Benzinga12:39 ET

How Peter Marks' FDA Departure Is Impacting Pharma, Biotech Stocks

Seeking Alpha12:37 ET

Novo-Nordisk A/S recorded its largest monthly decline in over 20 years. The long-term outlook remains Bullish, but the short-term rebound is lackluster.

①The Danish weight-loss drug giant Novo-Nordisk A/S has recorded its worst monthly performance in over twenty years; although Analysts remain Bullish on the stock's long-term prospects, there is a lack of catalysts expected to stimulate a rebound in the stock price in the short term. ② Since hitting an all-time high last June, the share price of Novo-Nordisk A/S has faced multiple setbacks.

cls.cn12:09 ET

Eli Lilly and Co's drug has achieved positive clinical results and is expected to reduce the risk of hereditary cardiovascular diseases.

①Eli Lilly and Co announced that its small interfering RNA therapy, lepodisiran, achieved positive results in Phase II clinical research, with the highest dose reducing participants' lipoprotein a levels by an average of 93.9% over 60 to 180 days; ②Elevated lipoprotein a levels are a common risk factor for heart disease and are difficult to lower even with lifestyle changes, affecting about one-fifth of the global population.

cls.cnMar 31 09:09 ET

Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug

BenzingaMar 31 09:07 ET